Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 TherapyGlobeNewsWire • 11/21/19
Iovance Biotherapeutics' (IOVA) CEO Maria Fardis on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
TIL Death Do Us Part: CAR T History Foreshadows Iovance's Destiny For OutperformanceSeeking Alpha • 10/02/19
Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual MeetingGlobeNewsWire • 10/02/19
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in SeptemberGlobeNewsWire • 08/26/19
Biotech Merger Activity Has Been Hot In 2019 — So, What's One More?Investors Business Daily • 08/02/19
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/02/19
Iovance stock up 2% after company gives positive regulatory update on potential cervical cancer treatmentMarket Watch • 07/02/19
Iovance Biotherapeutics Is The Next Biotech Takeover Candidate For Its Breakthrough TILs TechnologySeeking Alpha • 06/13/19